KR102953189B1 - 결절성 양진 환자에서 피부 병변 및 소양증의 치료 - Google Patents

결절성 양진 환자에서 피부 병변 및 소양증의 치료

Info

Publication number
KR102953189B1
KR102953189B1 KR1020217027603A KR20217027603A KR102953189B1 KR 102953189 B1 KR102953189 B1 KR 102953189B1 KR 1020217027603 A KR1020217027603 A KR 1020217027603A KR 20217027603 A KR20217027603 A KR 20217027603A KR 102953189 B1 KR102953189 B1 KR 102953189B1
Authority
KR
South Korea
Prior art keywords
ser
leu
pharmaceutical composition
thr
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217027603A
Other languages
English (en)
Korean (ko)
Other versions
KR20210122286A (ko
Inventor
크리스토쁘 피케티
Original Assignee
갈더마 홀딩 소시에떼 아노님
추가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 갈더마 홀딩 소시에떼 아노님, 추가이 세이야쿠 가부시키가이샤 filed Critical 갈더마 홀딩 소시에떼 아노님
Publication of KR20210122286A publication Critical patent/KR20210122286A/ko
Application granted granted Critical
Publication of KR102953189B1 publication Critical patent/KR102953189B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020217027603A 2019-01-28 2020-01-28 결절성 양진 환자에서 피부 병변 및 소양증의 치료 Active KR102953189B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962797803P 2019-01-28 2019-01-28
US62/797,803 2019-01-28
US201962809404P 2019-02-22 2019-02-22
US62/809,404 2019-02-22
PCT/IB2020/050623 WO2020157636A1 (en) 2019-01-28 2020-01-28 Treatment of skin lesions and pruritus in prurigo nodularis patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267011251A Division KR20260057215A (ko) 2019-01-28 2020-01-28 결절성 양진 환자에서 피부 병변 및 소양증의 치료

Publications (2)

Publication Number Publication Date
KR20210122286A KR20210122286A (ko) 2021-10-08
KR102953189B1 true KR102953189B1 (ko) 2026-04-15

Family

ID=69467604

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217027603A Active KR102953189B1 (ko) 2019-01-28 2020-01-28 결절성 양진 환자에서 피부 병변 및 소양증의 치료

Country Status (15)

Country Link
US (2) US11236157B2 (https=)
EP (1) EP3917617A1 (https=)
JP (4) JP7410852B2 (https=)
KR (1) KR102953189B1 (https=)
CN (1) CN113660981A (https=)
AU (2) AU2020213978A1 (https=)
BR (1) BR112021014854A2 (https=)
CA (1) CA3127983A1 (https=)
CL (1) CL2021001976A1 (https=)
IL (1) IL285171B2 (https=)
MX (1) MX2021009051A (https=)
PH (1) PH12021551805A1 (https=)
SG (1) SG11202108220YA (https=)
TW (1) TWI861052B (https=)
WO (1) WO2020157636A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021359068A1 (en) * 2020-10-15 2023-06-15 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha
US20220411518A1 (en) * 2021-04-07 2022-12-29 Galderma Holding S.A. Treatments for prurigo nodularis
WO2023044313A1 (en) * 2021-09-15 2023-03-23 Dermira, Inc. Il-13 inhibitors for the treatment of prurigo nodularis
US20240141050A1 (en) * 2022-09-02 2024-05-02 Galderma Holding S.A. Treatments for prurigo nodularis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046777A1 (fr) 1997-04-11 1998-10-22 Centre National De La Recherche Scientifique (Cnrs) Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
WO2010064697A1 (ja) 2008-12-05 2010-06-10 中外製薬株式会社 抗nr10抗体、およびその利用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE455852T1 (de) 1999-06-02 2010-02-15 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
US20120220948A1 (en) 2008-04-18 2012-08-30 Ipsyrng Capital Development, Llc Ergonomic syringe
DE102007056240A1 (de) 2007-11-22 2009-05-28 Henke-Sass, Wolf Gmbh Spritze
CA3199034C (en) 2015-08-24 2025-09-09 Dmk Pharmaceuticals Corporation SYRINGE-TYPE DEVICES
KR101900427B1 (ko) 2018-05-25 2018-09-20 송향숙 가압력 측정이 가능한 주사기용 보조그립

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046777A1 (fr) 1997-04-11 1998-10-22 Centre National De La Recherche Scientifique (Cnrs) Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
WO2010064697A1 (ja) 2008-12-05 2010-06-10 中外製薬株式会社 抗nr10抗体、およびその利用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chugai grants exclusive global liecnse for development and marketing of nemolizumab to Galderma, www.pharmabiz.com(2016.07.22. 온라인 공개)

Also Published As

Publication number Publication date
JP7410852B2 (ja) 2024-01-10
PH12021551805A1 (en) 2022-07-18
JP2022028788A (ja) 2022-02-16
JP2023182834A (ja) 2023-12-26
TW202043282A (zh) 2020-12-01
MX2021009051A (es) 2021-12-10
JP2021509103A (ja) 2021-03-18
CA3127983A1 (en) 2020-08-06
JP2023126909A (ja) 2023-09-12
US20220177568A1 (en) 2022-06-09
JP7671822B2 (ja) 2025-05-02
CL2021001976A1 (es) 2022-02-11
US20200239563A1 (en) 2020-07-30
IL285171B1 (en) 2025-11-01
TWI861052B (zh) 2024-11-11
AU2020213978A1 (en) 2021-09-23
JP7375252B2 (ja) 2023-11-07
WO2020157636A1 (en) 2020-08-06
US11236157B2 (en) 2022-02-01
CN113660981A (zh) 2021-11-16
KR20210122286A (ko) 2021-10-08
BR112021014854A2 (pt) 2021-12-21
IL285171B2 (en) 2026-03-01
IL285171A (en) 2021-09-30
AU2025263803A1 (en) 2025-11-27
SG11202108220YA (en) 2021-08-30
JP7309816B2 (ja) 2023-07-18
EP3917617A1 (en) 2021-12-08

Similar Documents

Publication Publication Date Title
JP7671822B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
CN112689512B (zh) 用于治疗银屑病的组合物和方法
CN109476733A (zh) 使用il-17拮抗剂治疗新发斑块型银屑病的方法
US20260008859A1 (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
KR20260057215A (ko) 결절성 양진 환자에서 피부 병변 및 소양증의 치료
RU2822134C2 (ru) Лечение поражений кожи и зуда у пациентов с узловатой почесухой
HK40130865A (en) Treatment of atopic dermatitis with moderate to severe excoriation
CN117940159A (zh) 结节性痒疹的治疗
HK40042731A (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
HK40042731B (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
HK40052952A (en) Compositions and methods for treatment of psoriasis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)